DK3049473T3 - Dobbeltderivatiserede chitosannanopartikler og fremgangsmåder til fremstilling og anvendelse heraf til genoverførsel in vivo - Google Patents

Dobbeltderivatiserede chitosannanopartikler og fremgangsmåder til fremstilling og anvendelse heraf til genoverførsel in vivo Download PDF

Info

Publication number
DK3049473T3
DK3049473T3 DK14846953.9T DK14846953T DK3049473T3 DK 3049473 T3 DK3049473 T3 DK 3049473T3 DK 14846953 T DK14846953 T DK 14846953T DK 3049473 T3 DK3049473 T3 DK 3049473T3
Authority
DK
Denmark
Prior art keywords
chitosananana
derivatized
vivo
returns
particles
Prior art date
Application number
DK14846953.9T
Other languages
English (en)
Inventor
Jun Gao
Eric Hsu
Anthony Cheung
Original Assignee
Engene Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engene Inc filed Critical Engene Inc
Application granted granted Critical
Publication of DK3049473T3 publication Critical patent/DK3049473T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/00272-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J5/00Manufacture of articles or shaped materials containing macromolecular substances
    • C08J5/005Reinforced macromolecular compounds with nanosized materials, e.g. nanoparticles, nanofibres, nanotubes, nanowires, nanorods or nanolayered materials
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Manufacturing & Machinery (AREA)
  • Cell Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Cosmetics (AREA)
DK14846953.9T 2013-09-25 2014-09-25 Dobbeltderivatiserede chitosannanopartikler og fremgangsmåder til fremstilling og anvendelse heraf til genoverførsel in vivo DK3049473T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361882500P 2013-09-25 2013-09-25
PCT/CA2014/050921 WO2015042711A1 (en) 2013-09-25 2014-09-25 Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo

Publications (1)

Publication Number Publication Date
DK3049473T3 true DK3049473T3 (da) 2022-01-03

Family

ID=52741681

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14846953.9T DK3049473T3 (da) 2013-09-25 2014-09-25 Dobbeltderivatiserede chitosannanopartikler og fremgangsmåder til fremstilling og anvendelse heraf til genoverførsel in vivo

Country Status (20)

Country Link
US (5) US10046066B2 (da)
EP (2) EP3970697A1 (da)
JP (5) JP6606490B2 (da)
KR (1) KR102295130B1 (da)
CN (1) CN105793345B (da)
AU (1) AU2014328439B2 (da)
BR (1) BR112016006620B1 (da)
CA (1) CA2925198C (da)
DK (1) DK3049473T3 (da)
ES (1) ES2900805T3 (da)
HU (1) HUE057565T2 (da)
IL (1) IL244715B (da)
MX (2) MX2016003747A (da)
PH (1) PH12016500565A1 (da)
PL (1) PL3049473T3 (da)
PT (1) PT3049473T (da)
SG (2) SG10202112747QA (da)
SI (1) SI3049473T1 (da)
WO (1) WO2015042711A1 (da)
ZA (1) ZA201602259B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3049473T3 (pl) 2013-09-25 2022-02-07 Engene, Inc. Podwójnie derywatyzowane nanocząstki chitozanu i sposoby ich wytwarzania i stosowania do transferu genów in vivo
CN104744716B (zh) * 2015-04-03 2018-03-09 广州康华微创生物科技有限公司 一种壳聚糖与改性聚乙烯醇复合膜的制备方法
CN104826132B (zh) * 2015-04-20 2018-07-24 南通大学 一种仿生siRNA胶束纳米复合物及应用
JP7750644B2 (ja) * 2016-11-09 2025-10-07 エンジーン,インコーポレイティド プログラム細胞死リガンド1の腸管発現
RU2019120163A (ru) * 2016-12-13 2021-01-15 Ам Сиенсес Инк Фармацевтическая композиция для предупреждения или лечения гепатита B
PH12021552216A1 (en) * 2019-03-14 2022-06-13 Engene Inc Chitosan polyplex-based localized expression of il-12 alone or in combination with type-i ifn inducers for treatment of mucosal cancers
CN110396524B (zh) * 2019-05-31 2023-05-02 海南大学 一种用于蚊虫的RNAi纳米颗粒和制备方法及用途
WO2021150997A2 (en) * 2020-01-22 2021-07-29 Engene, Inc. Localized expression of therapeutic nucleic acids in lung epithelial cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU685054C (en) 1992-05-14 2003-02-27 Baylor College Of Medicine Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy
US6004941A (en) 1993-06-14 1999-12-21 Basf Aktiengesellschaft Methods for regulating gene expression
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
AU2007285472B2 (en) 2006-03-30 2013-10-24 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
CA2848648C (en) 2006-06-02 2017-10-10 Synedgen, Inc. Chitosan-derivative compounds and methods of controlling microbial populations
KR100825519B1 (ko) * 2007-01-05 2008-04-25 주식회사 바이오폴리메드 키토산 기재 고분자 접합체 및 그 제조방법
WO2009036022A1 (en) * 2007-09-10 2009-03-19 Board Of Regents, The University Of Texas System Enhancement of polysaccharide-mediated nucleic acid delivery
SI2195035T1 (en) 2007-09-28 2018-05-31 Engene, Inc. High concentrations of chitosan-nucleic acid polypeptics of composites
EP2391387A1 (en) * 2009-01-29 2011-12-07 Synedgen, Inc. Nucleic acid delivery using modified chitosans
JP5907489B2 (ja) 2011-02-04 2016-04-26 国立大学法人 鹿児島大学 キトサン誘導体から得られるヒドロゲル
US9033930B2 (en) * 2011-12-22 2015-05-19 Avent, Inc. Base for an enteral feeding device
US9623112B2 (en) 2012-03-21 2017-04-18 Engene, Inc. Dually derivatized chitosan nanoparticles and methods of making and using the same
PL3049473T3 (pl) 2013-09-25 2022-02-07 Engene, Inc. Podwójnie derywatyzowane nanocząstki chitozanu i sposoby ich wytwarzania i stosowania do transferu genów in vivo

Also Published As

Publication number Publication date
AU2014328439B2 (en) 2018-06-28
ES2900805T3 (es) 2022-03-18
PL3049473T3 (pl) 2022-02-07
HUE057565T2 (hu) 2022-06-28
JP2025022907A (ja) 2025-02-14
IL244715B (en) 2020-07-30
JP2016536274A (ja) 2016-11-24
JP6606490B2 (ja) 2019-11-13
SI3049473T1 (sl) 2022-02-28
NZ718339A (en) 2021-11-26
KR20160084378A (ko) 2016-07-13
BR112016006620B1 (pt) 2021-06-22
US20180344875A1 (en) 2018-12-06
CA2925198C (en) 2021-12-07
ZA201602259B (en) 2019-07-31
US20220133907A1 (en) 2022-05-05
CN105793345B (zh) 2019-04-05
BR112016006620A2 (pt) 2017-08-01
SG10202112747QA (en) 2021-12-30
US20250127925A1 (en) 2025-04-24
JP2023071972A (ja) 2023-05-23
CN105793345A (zh) 2016-07-20
MX2016003747A (es) 2016-07-11
US10456481B2 (en) 2019-10-29
US20160235863A1 (en) 2016-08-18
EP3970697A1 (en) 2022-03-23
PT3049473T (pt) 2021-12-21
EP3049473B1 (en) 2021-09-22
WO2015042711A1 (en) 2015-04-02
EP3049473A1 (en) 2016-08-03
US20200061208A1 (en) 2020-02-27
MX2022000312A (es) 2022-02-10
US11167045B2 (en) 2021-11-09
CA2925198A1 (en) 2015-04-02
JP2021181441A (ja) 2021-11-25
US12076418B2 (en) 2024-09-03
JP6913144B2 (ja) 2021-08-04
SG11201602292SA (en) 2016-04-28
PH12016500565A1 (en) 2016-05-23
JP7244582B2 (ja) 2023-03-22
US10046066B2 (en) 2018-08-14
EP3049473A4 (en) 2017-05-24
KR102295130B1 (ko) 2021-08-31
AU2014328439A1 (en) 2016-04-21
IL244715A0 (en) 2016-04-21
JP2020033363A (ja) 2020-03-05

Similar Documents

Publication Publication Date Title
IL290547A (en) Antibodies and methods of use
IL280155A (en) Anti- SIGLEC-8 antibodies and methods of using them
SI3083689T1 (sl) Anti-CD3 protitelesa in načini uporabe
IL244495A0 (en) Anti-alpha-synuclein antibodies and methods of use
HRP20170840T1 (hr) Supstituirani ksantini i metode njihove uporabe
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK3082902T3 (da) Kropsbåret injektor og anvendelsesmetode
IL244643A0 (en) Anti-ly6e antibodies and methods of use
SMT202000162T1 (it) Nanoparticelle polimeriche terapeutiche e metodi per preparare e usare le stesse
DK3011041T3 (da) Biodieselsammensætning og dermed forbundet fremgangsmåde og produkter
DK2964767T3 (da) Toksingener og fremgangsmåder til anvendelse deraf
PL3052525T3 (pl) Przeciwciała anty- EpCAM i sposoby wykorzystania
EP2961765A4 (en) SMALL MOLECULAR PCSK9 MODULATORS AND METHOD OF USE THEREOF
DK2854822T3 (da) Polysaccharidsammensætninger og fremgangsmåder til anvendelse
IL245272B (en) pif-transfected cells and methods of use
DK3068428T3 (da) Annexin-ii-variant-sammensætninger og fremgangsmåder
HRP20180693T1 (hr) Novi postupak za sintezu 7-metoksi-naftalen-1-karbaldehida i njihova uporaba u sintezi agomelatina
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof